1-2 of 2
Shiyao Liu
Close
Save search
Sort by
Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Free
Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 2808.
https://doi.org/10.1182/blood-2019-122307
Published: 2019
Journal Articles

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

Free
C Waller, Gopinath M. Ranganna, Eduardo Pennella, Leonard A. Mattano, MD, Chien Chang Loa, Charles Donnelly, Mark Shiyao Liu, Heather Watson, Julien St-Jean, Sanjukta Chatterjee, Vivek Nayak, Nilanjan Sengupta, Mudgal A. Kothekar, Abhijit Barve
Journal: Blood
Blood (2017) 130 (Supplement 1): 3568.
https://doi.org/10.1182/blood.V130.Suppl_1.3568.3568
Published: 2017